This upside was driven by solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient demand. The adverse impact of removing the Average Manufacturer Price (AMP ...

Amanda Southcombe, GSK NZ general manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis ...

We need better utilisation of funding, more clinicians, and greater access to diagnostics,” he said. Amanda Southcombe, General Manager of GSK NZ, said recent funding for Trelegy Ellipta, a ...

Amanda Southcombe, GSK NZ General Manager, says funding for Trelegy Ellipta was recently announced, a single inhaler triple-therapy to treat the disease, which will see around 15,000 Kiwis suffering ...